#USA #New York #Pomerantz #uniQure #QURE

Pomerantz Law Firm Issues Investor Alert for uniQure N.V.

On April 2, 2026, Pomerantz LLP announced that a class action lawsuit has been initiated against uniQure N.V., a biotech company known for its innovative gene therapies, particularly targeting Huntington's disease. This legal action is aimed at protecting investors who may have suffered financial losses due to alleged securities fraud and misrepresentation by the company's officers and directors.

The lawsuit arises from uniQure's disclosure on November 3, 2025, concerning the feedback they received from the U.S. Food and Drug Administration (FDA) regarding their investigational gene therapy, AMT-130. In this announcement, uniQure indicated that the FDA no longer accepted their previously submitted data from clinical studies as adequate for their Biologics License Application (BLA) submission. This represented a significant shift from earlier communications with the agency, creating uncertainty regarding when they would be able to submit the BLA for AMT-130, directly impacting investor confidence.

As a result of the negative feedback from the FDA, uniQure's stock plummeted by $33.40 per share, amounting to a staggering 49.34% drop, leaving shareholders rattled and unsure of the company's future. This dramatic decline in share value underscored the potential ramifications of the allegedly deceptive practices that led to the proposed class action lawsuit.

Pomerantz LLP, an esteemed law firm recognized for its prowess in corporate and securities litigation, encourages affected investors to take immediate action. Those who purchased or acquired uniQure securities during the class period, which extends up until April 13, 2026, may be eligible to serve as Lead Plaintiffs in the lawsuit. Interested investors are urged to reach out to Danielle Peyton at Pomerantz LLP for additional information and to review the complaint, which can be accessed via their official website.

Pomerantz has a long-standing reputation for advocating on behalf of victims of corporate misconduct, recovering substantial settlements and damages for its clients. This firm, founded by early leading figures in class action, remains at the forefront of securities law, and continues its quest to enforce accountability among public companies and protect shareholders from undue financial harm.

The laws concerning class action suits exist to ensure that investors who have suffered similar losses can consolidate their claims and strengthen their bargaining position against larger corporate entities. By uniting to form a class, individuals can amplify their voices and seek justice collectively, thereby enhancing their chances of a favorable outcome against alleged wrongdoers.

Conclusion

In conclusion, uniQure's investors must act swiftly to join the class action lawsuit and take advantage of this opportunity to recover losses incurred during this tumultuous period. As the situation unfolds, Pomerantz LLP will continue to monitor developments closely, ensuring that they provide their clients with the most up-to-date information to navigate this complex legal landscape. For detailed inquiries and support in joining the lawsuit, investors can contact Pomerantz directly.

Corporate accountability is critical in fostering trust and integrity in the financial markets, and actions like this serve to remind companies of their responsibilities to shareholders. As the landscape of biotech continues to evolve, investors should remain vigilant and proactive in safeguarding their investments and rights.